Citi: Raises Dajin Heavy Industry (01081) target price to HK$34, reiterates "Buy" rating
Citi expects that Dajin Heavy Industry's new orders in Europe may begin to recover from the second quarter of 2027, depending on the progress of the new tariff regimes soon to be formulated in Germany and the UK.
Citi issued a research report stating that it has raised the target price for Dajin Heavy Industry (01081) by 13.3%, from HK$30 to HK$34, and reiterated its "Buy" rating. The bank expects that new orders from Europe may begin to recover starting in the second quarter of 2027, depending on the progress of new tariff regimes to be formulated in Germany and the United Kingdom.
Given that 4 to 5 monopiles will be shipped in the fourth quarter of 2026, the bank has raised its net profit forecast for Dajin Heavy Industry for 2026 by 19%; however, because the absence of new orders this year has led to a reduction in monopile shipment volumes and the gross margin of the shipment business has declined, the bank has lowered its net profit forecasts for 2027 to 2028 by 7% to 23%. The bank noted that Dajin Heavy Industry's share price has fallen 70% since its listing in June this year, reflecting the absence of new orders from Europe year to date.
Related Articles

CLSA: Cuts Semiconductor Manufacturing International Corporation (00981) H-share target price to HK$87.5, maintains "Outperform" rating

HK Stock Market Move | CARSGEN-B (02171) rose over 9% against the market trend as Kailemei became the first solid tumor CAR-T product in the commercial insurance innovative drug catalog.

HK Stock Market Move | YAOPOP (09929) once surged over 20%; the company has officially completed its name change; revenue of approximately HK$346 million was recorded in the first three quarters.
CLSA: Cuts Semiconductor Manufacturing International Corporation (00981) H-share target price to HK$87.5, maintains "Outperform" rating

HK Stock Market Move | CARSGEN-B (02171) rose over 9% against the market trend as Kailemei became the first solid tumor CAR-T product in the commercial insurance innovative drug catalog.

HK Stock Market Move | YAOPOP (09929) once surged over 20%; the company has officially completed its name change; revenue of approximately HK$346 million was recorded in the first three quarters.






